KR940013532A - 안구 피브린 형성 억제용 트롬빈 억제제의 용도 - Google Patents

안구 피브린 형성 억제용 트롬빈 억제제의 용도 Download PDF

Info

Publication number
KR940013532A
KR940013532A KR1019930027965A KR930027965A KR940013532A KR 940013532 A KR940013532 A KR 940013532A KR 1019930027965 A KR1019930027965 A KR 1019930027965A KR 930027965 A KR930027965 A KR 930027965A KR 940013532 A KR940013532 A KR 940013532A
Authority
KR
South Korea
Prior art keywords
inhibitor
per
body weight
thrombin
use according
Prior art date
Application number
KR1019930027965A
Other languages
English (en)
Inventor
뢰미슈 위르겐
파크스 에릭-폴
슐러 엑크하르트
Original Assignee
스타인, 하아스
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타인, 하아스, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인, 하아스
Publication of KR940013532A publication Critical patent/KR940013532A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 안구 피브린 형성 및 침착을 억제하기 위한 약제 제조 공정에서 가용성- 및 피브린- 및 세포-결합 트롬빈의 활성을 억제할 수 있는 물질 특히 히루딘, 이의 유도체, 이로부터 유도된 펩타이드 및 저분자량 트롬빈 억제제의 용도에 관한 것이다.

Description

안구 피브린 형성 억제용 트롬빈 억제제의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 안구 피브린 형성 및 침착을 억제하기 위한 약제의 제조방법에서 가용성 및 피브린- 및 세포-결합 트롬빈의 활성을 억제시킬 수 있는 물질의 용도.
  2. 제1항에 있어서, 트롬빈 억제제가 히루딘, 이의 유도체중 하나 또는 히루딘의 아미노산 서열로부터의 서열을 함유하는, 이로부터 유도된 펩타이드이거나 히루딘의 유사체 또는 통상적으로 작용성 등가물인 용도.
  3. 제1항에 있어서, 트롬빈 억제제가 저분자량 트롬빈 억제제인 용도.
  4. 제1항에 있어서, 트롬빈 억제제의 체중 1kg당 0.01mg 내지 20mg(경구 또는 정맥내 투여), 또는 체중 1kg당 0.01㎍ 내지 100㎍(안구내, 국소)의 농도로 사용하는 용도.
  5. 제1항에 있어서, 트롬빈 억제제를 체중 1kg당 0.05mg 내지 5mg(경구 또는 정맥내 투여), 또는 체중 1kg당 0.1㎍ 내지 10㎍(안구내, 국소)의 농도로 사용하는 용도.
  6. 제1항에 있어서, 추가로 플라즈민 억제제 또는 플라즈미노겐 활성화제 억제제를 함유한 약제 또는 팩단위를 제조하는 용도.
  7. 제1항에 있어서, 추가로 플라즈민 억제제 또는 플라즈미노겐 활성화제 억제제를 체중 1kg당 0.001mg 내지 50mg(경구/정맥내) 또는 체중 1kg당 0.001㎍ 내지 100㎍(안구내, 국소)을 함유한 약제 또는 팩단위를 제조하는 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930027965A 1992-12-17 1993-12-16 안구 피브린 형성 억제용 트롬빈 억제제의 용도 KR940013532A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4242655A DE4242655A1 (de) 1992-12-17 1992-12-17 Verwendung von Thrombin-Inhibitoren zur Inhibition okularer Fibrinbildung
DEP4242655.3 1992-12-17

Publications (1)

Publication Number Publication Date
KR940013532A true KR940013532A (ko) 1994-07-15

Family

ID=6475561

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930027965A KR940013532A (ko) 1992-12-17 1993-12-16 안구 피브린 형성 억제용 트롬빈 억제제의 용도

Country Status (7)

Country Link
EP (1) EP0603112A1 (ko)
JP (1) JPH06228006A (ko)
KR (1) KR940013532A (ko)
AU (1) AU675090B2 (ko)
CA (1) CA2111644A1 (ko)
DE (1) DE4242655A1 (ko)
NO (2) NO934653L (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
US5629324A (en) * 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
CA2404115A1 (en) * 2000-03-20 2001-09-27 Knoll Gmbh The use of peg-hirudin as an anticoagulant agent in the extracorporeal treatment of blood
WO2002050056A1 (en) 2000-12-18 2002-06-27 Merck & Co., Inc. Benzylamine derivatives and their use as thrombin inhibitors
US6528503B2 (en) 2000-12-18 2003-03-04 Merck & Co., Inc. Thrombin inhibitors
WO2002064559A2 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
US7084134B2 (en) 2002-05-02 2006-08-01 Merk & Co., Inc. Thrombin inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8203887D0 (sv) * 1982-06-23 1982-06-23 Kabivitrum Ab Nya trombininhiberande foreningar
DE3445532A1 (de) * 1984-12-13 1986-06-19 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn Hirudin-pa, desulfatohirudine-pa, verfahren zur herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten
GB8504025D0 (en) * 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
TW201303B (ko) * 1990-07-05 1993-03-01 Hoffmann La Roche
DE4111394A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel

Also Published As

Publication number Publication date
JPH06228006A (ja) 1994-08-16
NO934653L (no) 1994-06-20
AU5243693A (en) 1994-06-30
CA2111644A1 (en) 1994-06-18
NO934653D0 (no) 1993-12-16
AU675090B2 (en) 1997-01-23
EP0603112A1 (de) 1994-06-22
DE4242655A1 (de) 1994-06-23

Similar Documents

Publication Publication Date Title
Tamargo et al. Angiogenesis inhibition by minocycline
HUP0001914A2 (hu) Biokompatibilis vegyületek gyógyszerkészítményekhez
WO2002015903A3 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
ES2145913T3 (es) Inhibidores de metaloproteasas.
DE69921138D1 (de) Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel
HUP0400475A2 (hu) Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
RS49523B (sr) Vodeni farmaceutski rastvor
Smith Cefotaxime and cephalosporins: adverse reactions in perspective
KR940013532A (ko) 안구 피브린 형성 억제용 트롬빈 억제제의 용도
CA2141026A1 (en) Pharmaceutical Compositions for Transmucosal Delivery of Peptides
NO980858D0 (no) Farmasöytiske preparater og anordninger for administrering derav
ATE269098T1 (de) Verfahren zur vorbeugung von durch zyklosporine oder tacrolimus verursachter nierenvergiftung
Gabay et al. Studies of flavin-adenine dinucleotide-requiring enzymes and phenothiazines—II: Structural requirements for D-amino acid oxidase inhibition
Hasan et al. Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries
ATE223717T1 (de) Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen
AU7209594A (en) Anti-inflammatory peptides
RU95105249A (ru) Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения
GB2174905A (en) Compositions containing reduced glutathione
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
Innerfield et al. Plasma antithrombin alterations following oral papain
Lee et al. Oral peptide delivery: improving the systemic availability of small peptides and enkephalin analogs
DE50008113D1 (de) Dosieraerosole mit isobutan als treibmittel
Kuchkarov DIRECT THROMBIN INHIBITORS COMPARISON
DE69011692D1 (de) Therapeutische mittel.
DK1023059T3 (da) Farmaceutiske præparater

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application